Home - AVS Pulse, Inc

This Is IVL Amplified.^_TM

Calcified arterial disease is a significant challenge affecting patients around the world — one with limited treatment options. But a groundbreaking way to combat this dangerous disease is here: Pulse IVL™.

Discover Pulse IVL™

Different

Deliverable

Efficient

Easy to Use

A New Way to Combat Severe Calcified Arterial Disease

With its unique Mechanism of Action (MOA), Pulse IVL™ uses high-frequency pulsatile pressure waves to fracture arterial calcium. And through its improved deliverability and intuitive design, our innovative intravascular lithotripsy system is here to give healthcare providers an effective, efficient tool to help patients restore blood flow.

A New Era of IVL

Discover how Pulse IVL™ enables improved deliverability and empowers physicians to treat patients more effectively and efficiently.

A Fundamentally Different MOA

Our system uses a unique MOA — converting pressurized CO₂ into pulsatile energy waves at a rate of 15/second that uniformly and multi-directionally radiate along the entire length of the balloon to fracture calcium while expanding the vessel.

Learn More

Proficient from Pre-Clinical to Pivotal IDE

Developed to increase blood flow and improve patients’ ability to walk, Pulse IVL™ is establishing a new treatment option for calcified arterial disease.

Peripheral Clinical Evidence

In several pre-clinical models, Pulse IVL™ was shown to be effective in simultaneously achieving luminal expansion while producing full-thickness calcium fractures in diseased arteries in both concentric and eccentric lesions.

Learn More

Coronary Clinical Evidence

Due to the excellent results in treating calcified lesions in peripheral clinical models, we are working to achieve these same beneficial outcomes for patients with coronary artery disease.

Carotid Clinical Evidence

We believe the treatment efficiency benefits of Pulse IVL™ will be especially meaningful in treating carotid artery disease. Plans are underway to expand our system’s capabilities into carotid clinical models.

Trusted by Experts at the World’s Leading Hospitals

”

Nicolas W. Shammas, MD, FACS, FSCAI, FSVM, President and Director of the Midwest Cardiovascular Research Foundation

We found the device to be very deliverable and incredibly efficient at effectively modifying calcium and ultimately restoring blood flow to our patients’ vascular system.

”

Chris Metzger, MD, Interventional Cardiologist, National Principal Investigator of the POWER PAD II US IDE Study

By introducing a new, innovative treatment for calcified arterial disease, we can make a dramatic impact on patient lives and improve outcomes.

”

Jon George, MD, Interventional Cardiologist and Endovascular Medicine Specialist, Investigator in the POWER PAD I FIH Study

We have successfully demonstrated that we can treat patients with multiple lesions using a single device, while patients experienced a noted reduction in leg pain, increase in blood flow to the leg, and improvement in their ability to walk.

Keep Your Finger on the Pulse

Stay up to date on the latest announcements, press releases and more from AVS.

See More News

News

AVS Granted Innovation Award at ISET

AVS received the 2025 Innovation Award at the International Symposium on Endovascular Therapy (ISET), a premier annual event focused on advancements in endovascular techniques

AVS Completes a $36M Series B Financing Ahead of IVL U.S. Commercial Launch

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™

AVS Enrolls First Patient in U.S. Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has

AVS Partners with the Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy

AVS Brings New Approach to Lithotripsy: Vanguards of Health Care

In a Vanguards of Health Care podcast episode, AVS CEO, Mark Toland sits down with BI analyst Matt Henriksson for an in-depth interview to

Pulse IVL with Angie Volk & Sean Gilligan of AVS

Angie Volk, VP of Business Development at AVS, and Sean Gilligan, COO at AVS, recently sat down with Kyle Kruse and Richard Meiklejohn on

AVS Receives IDE Approval from FDA for Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has

AVS Appoints Elizabeth Galle as Vice President of Clinical Affairs

BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™

Cardio Conversations: AVS Talks about Starting a Company in a Pandemic, Cracking Peripheral Plaques and More

Robert Chisena, Ph.D., our CTO and Co-Founder, recently chatted with Reed Miller on the latest edition of the Cardio Conversations, a MedTech Insight podcast, to share his thoughts on our interventional technology,

AVS’ PIVL™ System in growing PAD market; Details on Medtech’s new digital playbook

AVS Chief Operating Officer, Sean Gilligan, recently sat down with Tom Salemi on the DeviceTalks podcast to discuss AVS’ approach to intravascular lithotripsy and the

Let’s Talk.

Looking to learn more about the innovative Pulse IVL™ or about AVS?

Reach Out Today

This Is IVL Amplified.^_TM

A New Way to Combat Severe Calcified Arterial Disease